

Synthesis and antitumor evaluation of some new substituted amidino-benzimidazolyl-furyl-phenyl-acrylates and naphtho[2,1-*b*]furan-carboxylates

M. Hranjec^a, M. Grdiša^b, K. Pavelic^b, D.W. Boykin^c, G. Karminski-Zamola^{a,*}

^a Department of Organic Chemistry, Faculty of Chemical Engineering and Technology, University of Zagreb, Marulicev trg 20, P.O. Box 177, HR-10000 Zagreb, Croatia

^b Division of Molecular Medicine, Ruder Boškovic Institute, Bijenicka cesta 54, P.O. Box 1016, HR-10000 Zagreb, Croatia

^c Department of Chemistry and Centre for Biotechnology and Drug Design, Georgia State University, Atlanta, GA 30303-3083, USA

Received 29 March 2003; accepted 19 July 2003

Abstract

The multistep synthesis of a series of substituted amidino-benzimidazolyl-furyl-phenyl-acrylic acid's esters and substituted amidino-benzimidazolyl-naphtho[2,1-*b*]furan-carboxylic acid's esters is described starting from corresponding 3-(2-furyl)-2-phenyl-acrylic acids. The new compounds were tested on the cytostatic activities against malignant cell lines: pancreatic carcinoma (MiaPaCa2), breast carcinoma (MCF7), cervical carcinoma (HeLa), laryngeal carcinoma (Hep2), colon carcinoma (HT 29), melanoma (HBL), and human fibroblasts cell line (WI38). All compounds inhibited the proliferation of tumor cell lines. Inhibitory effect of examined compounds depended on concentration, but without significant difference among the type of tumor cells. The compounds **2** and **5** exerted very low inhibitory effect on the growth of human fibroblasts. Unsubstituted derivative **8** has not inhibited any tested cell lines.

© 2003 Éditions scientifiques et médicales Elsevier SAS. All rights reserved.

Keywords: Pancreatic carcinoma; Laryngeal carcinoma; Breast carcinoma; Melanoma; Amidinobenzimidazolyl-furans

1. Introduction

Amidino-substituted aromatic and heteroaromatic compounds are widely investigated on their different biological activity in the recent time [1–12] including some phenyl substituted monoamidines which are synthesized and their anti HIV activity examined [13]. On the other side, there is no much literature evidence about the antitumor activity of amidines. A few papers describe the synthesis of the natural oligopeptide antiviral antibiotics *netropsyne* and *distamycine* and their synthetic derivatives. They have attracted considerable attention on the part of synthetic chemists and pharmacists because some representatives exhibit anticancer activity [14]. The effect of the synthetic derivative of *distamycine* on molecular interaction between DNA and

transcription factor Sp 1 were studied [15], while a new derivatives of *distamycine* bearing one or more pyrazole rings are synthesized and examined in vitro and in vivo activities against L1210 leukaemia [16]. DNA-binding properties and cytotoxic activity of novel aromatic amidines in cultured human skin fibroblasts were examined recently [17]. Antitumor activity of a series of cyclic amidines of benzodiazepine series was investigated too [18].

2. Results and discussion

In this paper we describe the preparation of six new substituted amidino-benzimidazolyl heterocyclic compounds from furan series which could serve as potential anticancer agent. The preparation of the target compounds is outlined in the scheme. Amidino compounds were prepared in the several steps from methyl (*Z*)-3-(5-formyl-2-furyl)-2-phenyl-acrylic acrylate, **1** [19] with

* Corresponding author.

E-mail address: gzamola@pierre.fkit.hr (G. Karminski-Zamola).

earlier prepared 3,4-diamino-substituted-benzamidines in the Pinner reaction [20,21]. In this way were prepared methyl ester of 3-[5-(*N*-isopropylamidino-benzimidazolyl)-2-furyl]-2-phenyl-acrylic acid **2**, 3-[5-(*N*-2-imidazolyl-benzimidazolyl)-2-furyl]-2-phenyl-acrylic acid **3** and 3-[5-(*N*-morpholinyl-amidino-benzimidazolyl)-2-furyl]-2-phenyl-acrylic acid **4** as hydrochloride salts. The prepared compounds **2**, **3** and **4** were photochemically dehydrogenated into methyl esters of 8-[5-(*N*-isopropylamidino-benzimidazolyl)naphtho[2,1-*b*]furan-5-carboxylic acid **5**, 8-[5-(*N*-2-imidazolyl-benzimidazolyl)naphtho[2,1-*b*]furan-5-carboxylic acid **6** and 8-[5-(*N*-morpholinyl-amidino-benzimidazolyl)naphtho[2,1-*b*]furan-5-carboxylic acid **7** as hydrochloride salts. Compound **4** photolitically rearranged into methyl ester of 8-(2-benzimidazolyl)naphtho[2,1-*b*]furan-5-carboxylic acid **8** by the prolonged irradiation in abs. ethanol (Scheme 1).

Structure identification of the synthetic products were determined by ^1H NMR, ^{13}C NMR spectroscopy and elemental analysis.

2.1. Biological activity

All new prepared compounds **2**, **3**, **4**, **5**, **6**, **7** and **8** were tested on their antitumor activity, using different

cell lines HeLa – cervical carcinoma, Hep2 – laryngeal carcinoma, HT29 – colon carcinoma, MiaPaCa2 – pancreatic carcinoma, HBL – melanoma, MCF7 – breast cancer and normal human fibroblasts – WI38. The inhibitory effect varied between the compounds, and depended on the concentration (as illustrated in Fig. 1).

All results are summarised in Table 1.

They are expressed as IC_{50} , a concentration at which compound inhibit the cell proliferation for 50%. Very strong inhibition was achieved on Hep2 ($\text{IC}_{50} = 1.66\text{--}39.8\ \mu\text{M}$), MiaPaCa2 ($\text{IC}_{50} = 2.45\text{--}46.7\ \mu\text{M}$), MCF7 ($\text{IC}_{50} = 2.63\text{--}10\ \mu\text{M}$) and HBL ($\text{IC}_{50} = 1.78\text{--}39.8\ \mu\text{M}$) cell lines. On the HeLa cells very good inhibition was achieved with compound **2**, **3**, **4**, **6** and **7** ($\text{IC}_{50} = 3.16\text{--}5.07\ \mu\text{M}$) and slight inhibition with compound **5** ($\text{IC}_{50} = 199\ \mu\text{M}$). Similar observation was on HT29 cell line. A compound **4** inhibited very strong HT29 cells ($\text{IC}_{50} = 1.38\ \mu\text{M}$), but other compounds exerted a wicker effect ($\text{IC}_{50} = 42.7\text{--}1580\ \mu\text{M}$). The best inhibition was achieved with compound **4**, but it inhibits also the growth of normal fibroblasts at the same extend ($\text{IC}_{50} = 5.5\ \mu\text{M}$). Very strong inhibition of all examined tumor cell lines was achieved with compound **2**, and without influence on proliferation of normal fibroblasts (WI38). To compare an inhibitory effect among the compounds, we can conclude that the basic structure of compounds **3**, **4**, **6** and **7** and substituents (**R**) did not influence on their inhibitory effect. But in compounds **2** and **5** the substituent (**R**) has an influence on the inhibitory effect. Unsubstituted derivative **8** has not inhibited any tested cell lines. Thus, the inhibitory effect moderated with substituent (**R**) and the concentration of substance, rather than with type of tumor cell line.


3. Experimental

3.1. General

Melting points were determined on a Kofler block apparatus and are uncorrected. IR spectra were determined with a Nicolet Magna 760 infrared spectrophotometer in KBr pellets. ^1H NMR and ^{13}C NMR spectral data were determined using Bruker Avance DPX 300 MHz NMR or Varian-Gemini 300 MHz spectrometers with tetramethylsilane as an internal standard. Elemental analyses were carried out in the Microanalytical laboratory at the 'Rugjer Boskovic' Institute.

3.2. Methyl *E*-3-(5-formyl-2-furyl)-2-phenylacrylate (**1**)

Corresponding methyl-*E*-3-(2-furyl)-2-phenylacrylate was formulated by Vilsmeier formulation.



3.4. Methyl *E*-3-{5-[5-*N*-(2-imidazolyl)-benzimidazolyl-2-furyl]}-2-phenylacrylate hydrochloride (3)

Compound **3** was prepared using the method described for the preparation of **2** from **1** (0.72 g, 2.8 mmol), 4-[*N*-(2-imidazolyl)]-1,2-phenylenediamine [21] (0.50 g, 2.8 mmol) and *p*-benzoquinone (0.30 g, 2.8 mmol) in abs. ethanol (25 ml). It was obtained 0.80 g, (54%) olive green powder m.p. 243–246 °C. IR (cm⁻¹; KBr): 3350, 1700, 1610. ¹H NMR (δ ppm) (DMSO-*d*₆): 10.76 (s, 2H, NH_{amid.}), 8.38 (s, 1H, NH_{benzimid.}, H-13), 7.91 (d, 1H, H_{arom.}, H-10, *J* = 8.64 Hz), 7.78 (d, 1H, H_{arom.}, H-11, *J* = 8.64 Hz), 7.70 (s, 1H, H_{arom.}, H-12), 7.50 (s, 1H, H_{ethen.}, H-7), 7.47–7.44 (m, 3H, H_{arom.}, H-2, H-3, H-4), 7.36 (d, 1H, H_{fur.}, H-9, *J* = 3.66 Hz), 7.30 (d, 1H, H_{arom.}, H-5, *J* = 7.80 Hz), 7.29 (d, 1H, H_{arom.}, H-1, *J* = 7.64 Hz), 5.68 (d, 1H, H_{fur.}, H-8, *J* = 3.66 Hz), 3.99 (bs, 4H, CH₂ imid.), 3.41 (s, 3H, H-6, OCH₃). ¹³C NMR (δ ppm) (DMSO-*d*₆): 166.3, 165.1, 151.9, 145.5, 145.0, 135.1, 131.8, 128.9, 128.7, 128.4, 126.6, 122.9, 115.9, 115.6, 114.9, 52.7, 44.2 (2C). *Anal.* Calc. for C₂₄H₂₂N₄O₃Cl₂·2H₂O: C 55.34, H 5.03, N 10.76; Found: C 55.73, H 4.81, N 10.75%.

3.5. Methyl *E*-3-{5-[5-*N*-(*N*-morpholinylamidino)-benzimidazolyl-2-furyl]}-2-phenylacrylate hydrochloride (4)

Compound **4** was prepared using the method described for the preparation of **2** from **1** (0.54 g, 2.1 mmol), 4-(*N*-morpholinylamidino)-1,2-phenylenediamine [21] (0.50 g, 2.1 mmol) and *p*-benzoquinone (0.23 g, 2.1 mmol) in abs. ethanol (25 ml). It was obtained 0.57 g, (54%) slightly green powder mp. 221–224 °C. IR (cm⁻¹; KBr): 3300, 1720, 1650, 1620. ¹H NMR (δ ppm) (DMSO-*d*₆): 11.17 (s, 1H, H_{amid.}), 9.81 (bs, 1H, NH_{amid.}), 9.11 (s, 1H, NH_{amid.}), 8.10 (s, 1H, H_{benzimid.}, H-13), 7.80 (d, 1H, H_{arom.}, H-10, *J* = 8.45 Hz), 7.73 (s, 1H, H_{arom.}, H-12), 7.65 (d, 1H, H_{arom.}, H-11, *J* = 8.48 Hz), 7.53 (s, 1H_{ethen.}, H-7), 7.52–7.49 (m, 3H, H_{arom.}, H-2, H-3, H-4), 7.36 (d, 1H, H_{fur.}, H-9, *J* = 3.8 Hz), 7.32 (d, 2H, H_{arom.}, H-1, H-5, *J* = 7.81 Hz), 5.71 (d, 1H, H_{fur.}, H-7, *J* = 3.6 Hz), 3.96 (s, 3H, H-6, OCH₃), 3.77 (t, 4H, 2CH₂ morph., *J* = 7.20 Hz), 2.94 (bs, 4H, 2CH₂ morph.). ¹³C NMR (δ ppm) (DMSO-*d*₆): 170.1, 166.3, 162.0, 152.2, 145.4, 144.5, 136.8, 132.1, 130.6, 130.1, 128.9, 128.4, 123.6, 120.5, 117.0, 116.4, 115.7, 115.6, 66.1, 53.8 (2C), 52.8 (2C). *Anal.* Calc. for C₂₆H₂₈N₅O₄Cl₃·2H₂O: C 50.61, H 5.24, N 11.35; Found: C 50.31, H 5.62, N 11.16%.

3.6. Methyl 2-[(5-*N*-isopropylamidino)benzimidazolyl]naphtho[2,1-*b*]furan-5-carboxylate hydrochloride (5)

A saturated solution of compound **2** (0.90 g, 2.0 mmol) in abs. ethanol (140 ml) was irradiated by pyrex filtered light with UV light of 400 W high pressure mercury arch lamp for 15 h at room temperature. Air was bubbled through the solution. Irradiated solution was concentrated under reduced pressure to 1/3 of the volume. Diethylether was added to the solution and the precipitated powder was filtered off and recrystallized from ethanol. It was obtained 0.37 g (35%) yellow powder m.p. 255–257 °C. IR (cm⁻¹; KBr): 3300, 1640. ¹H NMR (δ ppm) (DMSO-*d*₆): 9.62 (bs, 2H, NH_{amid.}), 9.52 (s, 1H, NH_{amid.}), 9.07 (s, 1H, NH_{benzimid.}, H-13), 8.88 (d, 1H, H_{arom.}, H-10, *J* = 8.67 Hz), 8.63 (s, 1H, H_{arom.}, H-12), 8.50 (d, 1H, H_{arom.}, H-11, *J* = 8.30 Hz), 8.47 (d, 1H, H_{arom.}, H-5, *J* = 7.60 Hz), 8.11 (s, 1H, H_{naphthofur.}, H-7), 7.87–7.70 (m, 3H, H_{arom.}, H-2, H-3, H-4), 7.63 (bs, 1H, H_{fur.}, H-9), 4.46 (m, 1H, CH_{i-pr.}), 4.07 (s, 3H, H-6, OCH₃), 1.24 (d, 6H, 2CH₃ i-pr., *J* = 6.21 Hz). ¹³C NMR (δ ppm) (DMSO-*d*₆): 167.5, 162.7, 158.9, 151.2, 148.7, 145.6, 143.8, 141.7, 128.3, 128.1, 127.5, 127.0, 126.3, 124.9, 124.3, 123.7, 117.3, 116.3, 115.7, 108.4, 53.1, 45.6, 21.9. *Anal.* Calc. for C₂₅H₂₄N₄O₃Cl₂·2H₂O: C 56.12, H 5.27, N 10.47; Found: C 56.30, H 5.16, N 10.72%.

3.7. Methyl 2-[(5-*N*-(2-imidazolyl)]benzimidazolyl]naphtho[2,1-*b*]furan-5-carboxylate hydrochloride (6)

Compound **6** was prepared on the way described for **5** by irradiation of saturated solution of **3** (0.50 g, 1.1 mmol) in ethanol: water (15 ml: 10 ml) during 35 h. It was obtained 0.075 g (16%) yellow–green powder, m.p. > 300 °C. IR (cm⁻¹; KBr): 3350, 1690. ¹H NMR (δ ppm) (DMSO-*d*₆): 10.67 (bs, 2H, NH_{amid.}), 8.87 (d, 1H, H_{arom.}, H-10, *J* = 8.98 Hz), 8.59 (s, 1H, NH_{benzimid.}, H-13), 8.53 (d, 1H, H_{arom.}, H-11, *J* = 8.54 Hz), 8.46 (s, 1H, H_{arom.}, H-12), 8.44 (d, 1H, H_{arom.}, H-5, *J* = 7.38 Hz), 7.90 (bs, 1H, H_{arom.}, H-2), 7.84 (s, 1H, H-7), 7.80–7.70 (m, 2H, H_{arom.}, H-3, H-4), 7.65 (s, 1H, H_{furan.}, H-9), 4.25–4.21 (bs, 4H, 2CH₂ imid.), 4.16 (s, 3H, H-6, OCH₃). ¹³C NMR (δ ppm) (DMSO-*d*₆): 166.8, 165.0, 150.6, 148.1, 146.5, 142.2, 127.6, 127.5, 127.4, 127.3, 126.8, 126.3, 125.2, 124.3, 123.0, 116.1, 115.6, 115.4, 107.8, 107.3, 52.5, 44.2 (2C). *Anal.* Calc. for C₂₄H₂₀N₄O₃Cl·3H₂O: C 53.67, H 4.88, N 10.43; Found: C 53.66, H 4.87, N 10.68%.

3.8. *Methyl 2-{5-[5-N-(N-morpholinylamidino)]benzimidazolyl}naphtho[2,1-b]furan-5-carboxylate hydrochloride (7)*

Compound **7** was prepared on the way described for **5** by irradiation of saturated solution of **4** (0.75 g, 1.5 mmol) in abs. ethanol (150 ml) during 10 h. It was obtained 0.21 g (23%) yellow powder, mp. 270–272 °C. IR (cm⁻¹; KBr): 3300, 1650. ¹H NMR (δ ppm) (DMSO-*d*₆): 11.32 (bs, 1H, NH_{amid.}), 9.85 (bs, 1H, NH_{amid.}), 9.20 (s, 1H, NH_{amid.}), 8.23 (bs, 1H, NH_{benzimid.}, H-13), 7.90 (d, 1H, H_{arom.}, H-10, *J* = 8.40 Hz), 7.85 (s, 1H, H_{arom.}, H-12), 7.77 (d, 1H, H_{arom.}, H-11, *J* = 8.70 Hz), 7.70 (s, 1H, H-7), 7.68 (d, 1H, H_{arom.}, H-5, *J* = 7.80 Hz), 7.48–7.37 (m, 3H, H_{arom.}, H-2, H-3, H-4), 7.28 (bs, 1H, H_{fur.}, H-9), 3.76 (bs, 4H, 2CH₂ morph.), 3.72 (s, 3H, H-6, OCH₃), 2.96 (bs, 4H, 2CH₂ morph.). ¹³C NMR (δ ppm) (DMSO-*d*₆): 162.20, 162.12, 161.57, 150.66, 148.27, 145.41, 129.03, 128.49, 127.72, 127.61, 127.54, 127.50, 125.68, 125.62, 125.14, 124.41, 123.03, 122.75, 120.31, 116.17, 115.78, 115.05, 65.51 (2C), 62.02 (2C). *Anal.* Calc. for C₂₆H₂₆N₅O₄Cl₃·3H₂O: C 49.37, H 5.10, N 11.07; Found: C 49.38, H 5.31, N 11.21%.

3.9. *Methyl 2-(benzimidazolyl)naphtho[2,1-b]furan-5-carboxylate (8)*

When the saturated solution of compound **4** (0.25 g, 0.5 mmol) in abs. ethanol (35 ml) was prolonged irradiated (during 15 h and in the quantity of the 1/3 of the experiment 3.8) by pyrex filtered light with UV light of 400 W high pressure mercury arch, only photolitic product **8** (after recrystallization in ethanol) was isolated in the yield of 0.015 g (14%). Yellow powder m.p. 230–232 °C. IR (cm⁻¹; KBr): 3310, 1650. ¹H NMR (δ ppm) (DMSO-*d*₆): 8.87 (d, 1H, H_{arom.}, H-10, *J* = 8.87 Hz), 8.55 (s, 1H, NH_{benzimid.}, H-13), 8.54 (d, 1H, H_{arom.}, H-11, *J* = 8.50 Hz), 8.45 (s, 1H, H_{arom.}, H-12), 8.22 (s, 1H, H-7), 7.83 (d, 1H, H_{arom.}, H-5, *J* = 7.60 Hz), 7.81 (s, 1H, H_{fur.}, H-9), 7.76 (d, 1H, H_{arom.}, H-2, *J* = 7.70 Hz), 7.72 (dd, 1H, H_{arom.}, H-4, *J*₁ = 8.40 Hz, *J*₂ = 8.38 Hz), 7.66 (dd, 1H, H_{arom.}, H-3, *J*₁ = 8.36 Hz, *J*₂ = 8.40 Hz), 4.44 (s, 3H, H-6, OCH₃). ¹³C NMR (δ ppm) (DMSO-*d*₆): 167.5, 151.2, 148.6, 146.0, 128.2, 128.1, 128.0 (2C), 127.4, 126.9, 126.2, 125.0, 121.7, 120.3, 116.5, 116.2, 108.2, 105.3, 53.1. *Anal.* Calc. for C₂₁H₁₄N₂O₃: C 70.06, H 4.48, N 7.78; Found: C 70.35, H 4.24, N 8.03%.

3.10. *Biological assays*

Biological activity of the compounds **2**, **3**, **4**, **5**, **6**, **7** and **8** was measured by their influence on growth of cell cultures in vitro. The following human carcinoma cell lines were used: HeLa (cervical carcinoma), Hep2 (laryngeal carcinoma), HT29 (colon carcinoma), Mia-

PaCa2 (pancreatic carcinoma), HBL (melanoma), MCF7 (breast cancer) and normal human fibroblasts WI38. The cells were treated with different concentration of compounds (10⁻⁴, 10⁻⁵, 10⁻⁶ M) during 72 h. All cell lines were grown in DMEM medium (supplemented with 10% heat inactivated fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin) at 37 °C in a humidified atmosphere with 5% CO₂. For the purpose of the experiment, the cells were plated in 96-microwell flat bottom plates at a concentration of 2 × 10⁴ cells/ml (all tumor cell lines) and 3 × 10⁴ cells/ml (WI38). The next day (24 h later) compounds were added to the cells at different concentrations (10⁻⁴, 10⁻⁵ and 10⁻⁶ M). Compounds were dissolved in DMSO at a concentration of 10⁻¹ M and diluted with DMEM medium into working concentrations. The concentration of DMSO was less than 0.1% and at that concentration it does not affect the growth. Control cells (without any compound) were growing under the same conditions. Cell viability was measured at day 0 and 72 h after addition of compounds, using MTT assay, which detects dehydrogenase activity in viable cell [22]. For this purpose the medium was discarded and MTT was added to each well at a concentration of 20 µg/40 µl. After 4 h of incubation at 37 °C, the precipitates were dissolved in 160 µl of DMSO. The absorbance was measured on an ELISA reader at 570 nm, and the percentage of growth was calculated. Each number was the mean of three individual experiments done in quadruplicate. The results are expressed as IC₅₀, what represent a concentration for 50% inhibitory effect.

Acknowledgements

Support for this study by the Ministry of Science (Project No 0125005 and 00981104) is gratefully acknowledged.

References

- [1] M.A.H. de Zwart, H. van der Goot, H. Timmerman, Synthesis and copper-dependent antimycoplasmal activity of 1-amino-3-(2-pyridyl)isoquinoline derivatives. 2. Amidines, *J. Med. Chem.* 32 (1989) 487–493.
- [2] M.M. Canto-Cavalheiro, A. Echevarria, M.A.S. de Souza, L. Cysne-Finkelstein, M.A.D. Torres, L.L. Leon, Effect on amidine derivatives on leishmania amazonensis axenic amastigotes, *Arzneimittel-Forschung* 50 (2000) 925–928.
- [3] K. Okumura, T. Shimazaki, Y. Aoki, H. Yamashita, New platelet fibrinogen receptor glycoprotein II B–III A antagonists-orally active series of *N*-alkylated amidines with A 6,6-bicyclic twemplate, *J. Med. Chem.* 41 (1998) 4036–4052.
- [4] T.W. Ku, W.H. Miller, W.E. Bondinell, K.F. Erhard, R.M. Keenan, A.J. Nicholas, C.E. Peishoff, J.M. Samanen, A.S. Wong, W.F. Huffman, Potent non-peptide fibrinogen receptor antago-

- nists which present alternative pharmacophore, *J. Med. Chem.* 38 (1987) 9–12.
- [5] E.S.H. El Ashry, N. Rashed, A.H.S. Shobier, Glycosidase inhibitors and their chemotherapeutic value, part 3 (review), *Pharmazie* 55 (2000) 403–415.
- [6] T.M. Sielecki, J. Liu, S.A. Mousa, A.L. Racanelli, E.A. Hausner, R.R. Wexler, R.E. Olson, Synthesis and pharmacology of modified amidine isoxazoline glycoprotein IIb/IIIa receptor antagonists, *Bioorgan. Med. Chem. Lett.* 11 (2001) 2201–2204.
- [7] W.R. Ewing, M.R. Becker, V.E. Manetta, R.S. Davis, et al., Design and structure–activity relationship of potent and selective inhibitors of blood coagulation factor Xa, *J. Med. Chem.* 42 (1999) 3557–3571.
- [8] R. Ferroni, D. Simoni, S. Manfredini, M. Guarneri, P. Orlandini, M. Barbieri, G.P. Franzè, A. Mugelli, Synthesis of N₁-substituted benzamidines. Effect on blood coagulation, platelet aggregation and antiarrhythmic activity, *Arzneimittel-Forschung* 45 (1995) 665–669.
- [9] J.M. Mellor, H. Rataj, A general route to cyclic amidines and isothioureas based on formal Aza Diels Alder reactions of aminoheterocycles, *Tetrahedron Lett.* 37 (1996) 2619–2622.
- [10] M.J. Rudolph, C.R. Illig, N.L. Subasinghe, et al., Design and synthesis of 4,5-disubstituted-thiophene-2-amidines as potent ur-kinase inhibitors, *Bioorgan. Med. Chem. Lett.* 12 (2002) 491–495.
- [11] J.L. Collins, B.G. Shearer, J.A. Oplinger, S. Lee, E.P. Garvey, M. Salter, C. Duffy, T.C. Burnette, E.S. Furfine, *N*-Phenylamidines as selective inhibitors of human neuronal nitric oxide synthase: structure–activity studies and demonstration of *in vivo* activity, *J. Med. Chem.* 41 (1998) 2858.
- [12] C.E. Stephens, F. Tanious, S. Kim, D.W. Wilson, W.A. Schell, J.R. Perfect, S.G. Franzblau, D.W. Boykin, Diuanidino and reversed diamidino-2,5-diarylfurans as antimicrobial agents, *J. Med. Chem.* 44 (2001) 1741.
- [13] A. Echevarria, L.H. Santos, J. Miller, N. Mahmood, Synthesis, characterization and anti-HIV activity of some 2-p-X-phenyl-1,3-*N,N'*-diphenyl-amidines, *Bioorgan. Med. Chem. Lett.* 6 (1996) 1901–1904.
- [14] J.W. Lown, K. Krowicki, Efficient total syntheses of the oligopeptide antibiotics netropsin and dystamicin, *J. Org. Chem.* 50 (1985) 3774–3779.
- [15] P.G. Baraldi, G. Cacciari, A. Guiotto, R. Romagnoli, et al., [2,1-c] [1,4]Benzodiazepine (PBD)-dystamicin hybrid inhibits DNA binding to transcription factor Sp1, *Nucleosides, Nucleot. Nucl. Acids* 19 (2000) 1219–1229.
- [16] P.G. Baraldi, P. Cozzi, C. Geroni, N. Mongelli, et al., Novel benzoyl nitrogen mustard derivatives of pyrazole analogues of distamicin a: synthesis and antileukemic activity, *Bioorgan. Med. Chem.* 7 (1999) 251–262.
- [17] A. Bielawska, K. Bielawski, S. Wolczynski, DNA-binding properties and cytotoxicity activity of novel aromatic amidines in cultured human skin fibroblasts, *Pharmazie* 56 (2001) 428–429.
- [18] R. Janciene, L. Kosychova, V. Bukelskiene, V. Domkus, Z. Strumbreviciute, V. Ragaleviciene, B.D. Puodziunaite, Synthesis and antitumor activity of a series of cyclic amidines of 2,3-dihydro-1H-1,5-benzodiazepines, *Arzneimittel-Forschung* 52 (2002) 475–481.
- [19] M. Bajić, G. Karminski-Zamola, N. Blazević, Twofold photochemical dehydrocyclization reaction of substituted 2,5-distyrylthiophenes and 2,5-distyrylfuranes, *Croat. Chem. Acta* 65 (1992) 835–846.
- [20] R.R. Tidwell, Antipneumocystis activities of aromatic diamidoxime prodrugs, *Antimicrob. Agents Chemother.* (1998) 666–674.
- [21] T.A. Farley, R.R. Tidwell, I. Donkor, N.A. Naiman, K.A. Ohemeng, R.J. Lombardy, J.A. Bentley, M. Cory, Structure, DNA minor groove binding, and base pair specificity of alkyl- and aryl-linked bis(amidinobenzimidazoles) and bis(amidinoin- doles), *J. Med. Chem.* 36 (1993) 1746–1753.
- [22] J. Carmichael, W.G. DeGraff, A.F. Gazdar, J.D. Minna, J.B. Mitchell, Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing, *Cancer Res.* 47 (1987) 936–942.